Table 1 Correlation between IRF-2 and clinicopathologic characteristics
From: IRF-2 inhibits cancer proliferation by promoting AMER-1 transcription in human gastric cancer
Total | IRF-2 expression | P value | ||
|---|---|---|---|---|
Low (35) | High(37) | |||
Sex | ||||
Male | 55 | 28 (50.9) | 27 (49.1) | 0.483 |
Female | 17 | 7 (41.2) | 10 (58.5) | |
Age(y) | ||||
< 60 | 34 | 16 (47.1) | 18 (52.9) | 0.803 |
≥ 60 | 38 | 19 (50.0) | 19 (50.0) | |
Histological grade | ||||
G1–2 | 32 | 18 (56.3) | 14 (43.7) | 0.460 |
G3 | 40 | 19 (47.5) | 21 (52.5) | |
Invasive depth | ||||
Mucosa to muscularis propria | 21 | 9 (42.9) | 12 (60.6) | 0.150 |
Adventitia to adjacent structure | 51 | 22 (56.4) | 17 (43.6) | |
Lymph nodes metastasis | ||||
≤ 2 regions | 33 | 13 (39.4) | 20 (30.77) | 0.407 |
> 2 regions | 39 | 31 (60.78) | 20 (39.22) | |
Distant metastasis | ||||
Yes | 8 | 6 (75.0) | 2 (25.0) | 0.146 |
No | 64 | 29 (45.3) | 35 (54.7) | |
Position | ||||
Antrum and gastric angle | 32 | 14 (43.8) | 18 (56.3) | 0.460 |
Others | 40 | 21 (52.5) | 19 (47.5) | |
Size | ||||
< 4 cm | 27 | 13 (48.1) | 14 (51.9) | 0.951 |
≥ 4 cm | 45 | 22 (48.9) | 23 (51.1) | |
TNM stage | ||||
I, II | 28 | 12 (42.9) | 16 (57.1) | 0.436 |
III, IV | 44 | 23 (52.3) | 21 (47.7) | |